HeartBeam, Inc.

HeartBeam, Inc. is a medical technology company based in Santa Clara, California, focused on developing advanced ambulatory Electrocardiogram (ECG) solutions. The company's mission is to transform cardiac care by providing clinical-grade ECG insights outside traditional clinical settings, empowering both patients and physicians with actionable cardiac data at the onset of arrhythmia symptoms.

The company's core technology is a proprietary and patented Vector Electrocardiography (VECG) platform, which includes a credit card-sized, cable-free 3D ECG device. This device captures the heart's electrical signals in three dimensions and synthesizes them into a 12-lead ECG for arrhythmia assessment. HeartBeam offers an app-based solution for rhythm monitoring, cloud-based diagnostic software, and has partnered with HeartNexus for a 24/7 cardiologist reader service. The company targets market segments such as remote patient monitoring and hospital emergency rooms, with an initial commercialization strategy focused on high-value preventive cardiology practices.

HeartBeam has achieved significant regulatory milestones, including FDA 510(k) clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. Led by CEO Robert Eno, the company is entering its initial commercialization phase and recently closed a $10 million public offering in April 2026 to support these efforts and further development. HeartBeam is also engaged in a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-driven cardiac monitoring and develop predictive algorithms.